90 trials (keyword fallback)
Uterine Fibroids · Uterine Leiomyomata
Primary: Treatment-related Adverse Events (AE) Per Subject Resulting From HIFU Treatment of the Uterine Fibroids — 1.3 treatment-related AE/patient
Pain · Hysterectomy · Myomectomy
Primary: Quality of Surgical Field Visualization — 9; 1; 5; 2 participants
Urinary Retention · Voiding Disorders
Primary: Number of Participants With Void Trial Failure Rate — 7; 11 Participants
Pelvic Organ Prolapse
Primary: Number of Participants With Recurrence of Pelvic Organ Prolapse — 0; 0 Participants
Endometrial Cancer
Primary: Health Related Quality of Life (HRQoL) — 0.34; 0.30; 0.66; 0.48 scores on a scale — p=0.011
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
Pain, Postoperative
Primary: Post-operative Pain Score — 4; 4.5 units on a scale
Laparoscopic Hysterectomy
Primary: Change in Bleeding at Specified Time Intervals — 485.7; 199.1 seconds
Menorrhagia
Primary: Menstrual Blood Loss (MBL) as Measured by Pictorial Blood Loss Assessment Chart (PBLAC). — 15; 0 units on a scale — p=0.003
Pain, Postoperative
Primary: Total Opioid Pain Medications Required 0-3h Post op in Morphine Milligram Equivalents (MME) — 2.00; 5.32 morphine milligram equivalents (MME)
Uterine Diseases
Primary: Successful Removal of the Uterus Without Conversion to Another Technique — 35; 35 Participants — p=0.0221
Pain, Postoperative
Primary: Pain Reported on the Visual Analogue Scale (VAS) at 30 Minutes Postoperative — 5.7; 3.2 VAS scale 0-10
Blood Loss During Vaginal Hysterectomy
Primary: Intra-operative Blood Loss During Vaginal Hysterectomy
Cervical Cancer
Primary: Pelvic Recurrence Rate at 3 Years — 2.17; 2.52 percentage of participants
Acute Pain
Primary: Post Operative Opioid Use — 24.9; 51.7 micrograms of fentanyl equivalents